PUMA BIOTECHNOLOGY, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PUMA BIOTECHNOLOGY, INC. stock issued during period, value, stock options exercised for the quarter ending 2017-09-30 was $9.73M, a 7443.41% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. stock issued during period, value, stock options exercised for the quarter ending 2017-06-30 was $3.56M.
- PUMA BIOTECHNOLOGY, INC. stock issued during period, value, stock options exercised for the quarter ending 2017-03-31 was $706.00K, a 218.02% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. stock issued during period, value, stock options exercised for the quarter ending 2016-12-31 was $225.00K, a 82.95% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. stock issued during period, value, stock options exercised for fiscal 2016 was $576.00K, a 97.96% decline from fiscal 2015.
- PUMA BIOTECHNOLOGY, INC. stock issued during period, value, stock options exercised for fiscal 2015 was $28.23M, a 332.08% increase from fiscal 2014.
- PUMA BIOTECHNOLOGY, INC. stock issued during period, value, stock options exercised for fiscal 2014 was $6.53M, a 194.94% increase from fiscal 2013.
- PUMA BIOTECHNOLOGY, INC. stock issued during period, value, stock options exercised for fiscal 2013 was $2.21M, a 4822.22% increase from fiscal 2012.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2017-09-30 | $9.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $14.23M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $3.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $4.63M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $706.00K 10-Q · filed 2017-05-10 | $1.06M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $225.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $576.00K 10-K · filed 2019-03-01 |
| 2016-09-30 | $129.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $1.67M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $6.92M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-03-31 | $222.00K 10-Q · filed 2016-05-10 | $14.01M derived: sum of 4 quarters · filed 2018-03-09 |
| 2015-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $28.23M 10-K · filed 2018-03-09 |
| 2015-09-30 | $5.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | |
| 2015-06-30 | $7.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | |
| 2015-03-31 | $14.44M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $6.53M 10-K · filed 2017-03-01 | |
| 2013-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $2.21M 10-K · filed 2016-02-29 |
| 2012-12-31 | $45.00K 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |